choroba
Nearly 83 percent patients with early-stage Alzheimer's disease achieved disease stabilization or improvement after an average of 17 months of treatment with lekanemab. The results of the RWE (Real World Evidence) LEADER study confirm the long-term benefits of treatment in everyday…
Peak volume
1K+
First seen
2026-08-07
Last seen
2026-08-07
Days trending
1 / 1
Countries
2